ArticleOrphanet journal of rare diseases2026
Analysis of homocysteine levels in carriers with MMACHC gene variants.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveVariants in the MMACHC gene cause combined methylmalonic acidemia (MMA) and homocystinuria, cobalamin C (cblC) type. This study aimed to determine whether heterozygous MMACHC variant carriers exhibit elevated plasma homocysteine (Hcy) levels and to explore the variant-type-specific biochemical effects.
methodsIn this prospective study, 301 MMACHC variant carriers and 304 controls were enrolled. Plasma Hcy levels, demographic characteristics, and clinical data were collected. Propensity score matching (PSM, 1:1) was performed to balance age and sex between groups. Generalized linear models were applied to investigate the correlation between MMACHC variant carriage and Hcy levels.
resultsAfter PSM, 173 carrier-control pairs were included. Carriers showed significantly higher Hcy levels (median 12.27 µmol/L, range 5.30-85.90) than controls (9.80 µmol/L, 3.10-53.30; P < 0.001). Both Male sex (β = 7.816, 95% CI:5.746-9.887) and MMACHC variant carriage (β = 5.741, 95%CI:3.743-7.740) were independently associated with elevated Hcy. Among carriers, missense variants, especially c.80A > G (p.Q27R), were correlated with higher Hcy levels.
conclusionHeterozygous MMACHC variant carriers had higher plasma Hcy levels than age- and sex-matched controls in this study. Missense variants and male sex tended to be associated with higher Hcy levels. These findings suggest that MMACHC variant carriers can present with biochemical abnormalities and associated with alterations in homocysteine metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.